CellProthera

The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology an

John Tsai, formerly chief medical officer at Novartis , has been appointed the new CEO at Forcefield Therapeutics , a biotech working on a recombinant protein-based therapy aimed at saving heart cel